Butenandt O, Staudt B
Dr. von Haunersches Kinderspital der Universität, München, Federal Republic of Germany.
Eur J Pediatr. 1989 Feb;148(5):393-5. doi: 10.1007/BF00595894.
Seven children with growth hormone deficiency of hypothalamic origin responded to an i.v. bolus of growth hormone releasing hormone (GHRH) (1-29)-NH2 with a mean serum increase of 10.7 ng/ml growth hormone (GH) (range 2.5-29.3 ng/ml). Continuous s.c. administration of GHRH of 4-6 micrograms/kg twice daily for at least 6 months did not improve the growth rate in five of the patients. One patient increased his growth rate from 1.9 to 3.8 cm/year and another from 3.5 to 8.2 cm/year; however, the growth rate of the latter patient then decreased to 5.4 cm/year. When treatment was changed to recombinant human growth hormone (rhGH) in a dose of 2 U/m2 daily, given s.c. at bedtime, the growth rate improved in all patients to a mean of 8.5 cm/year (range: 6.2 to 14.6). Presently GHRH cannot be recommended for the routine therapy of children with growth hormone deficiency since a single daily dose of rhGH produced catch-up growth which GHRH therapy did not.
7名下丘脑源性生长激素缺乏的儿童对静脉注射一次生长激素释放激素(GHRH)(1 - 29)-NH₂有反应,血清生长激素(GH)平均增加10.7 ng/ml(范围为2.5 - 29.3 ng/ml)。5例患者每日两次皮下持续注射4 - 6微克/千克的GHRH,至少6个月,生长速率未改善。1例患者生长速率从1.9厘米/年增至3.8厘米/年,另1例从3.5厘米/年增至8.2厘米/年;然而,后1例患者的生长速率随后降至5.4厘米/年。当治疗改为每日剂量2 U/m²的重组人生长激素(rhGH),睡前皮下注射时,所有患者的生长速率均提高,平均为8.5厘米/年(范围:6.2至14.6)。目前,GHRH不推荐用于生长激素缺乏儿童的常规治疗,因为每日单次剂量的rhGH可产生追赶生长,而GHRH治疗则不能。